Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients

Shimony, Avi; Zahger, Doron; Gilutz, Harel; Goldstein, Hagit; Orlov, Gennady; Merkin, Miri; Shaleṿ, Aryeh; Ilia, Reuben; Douvdevani, Amos

doi:10.3109/17482941.2010.513732

Cited by 66 publications

(46 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First discovered in 1948 by Mandel and Metais, fragmented DNA or cfDNA has since been associated with a number of conditions, including end-stage renal disease, myocardial infarction, stroke, and trauma [2][3][4][5][6][7]. Multiple studies have shown a correlation between the levels of cfDNA and cellular injury and necrosis, processes relevant in cancer cell survival and propagation.…”

Section: Cfdnamentioning

confidence: 99%

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Levy

Cordova

et al. 2016

The Oncologist

View full text Add to dashboard Cite

A firmer understanding of the genomic landscape of lung cancer has recently led to targeted, therapeutic advances in non-small cell lung cancer. Historically, the reference standard for the diagnosis and genetic interrogation for advanced-stage patients has been tissue acquisition via computed tomography-guided core or fine needle aspiration biopsy. However, this process can frequently put the patient at risk and remains complicated by sample availability and tumor heterogeneity. In addition, the time required to complete the diagnostic assays can negatively affect clinical care. Technological advances in recent years have led to the development of blood-based diagnostics or “liquid biopsies” with great potential to quickly diagnose and genotype lung cancer using a minimally invasive technique. Recent studies have suggested that molecular alterations identified in cell-free DNA (cfDNA) or circulating tumor DNA can serve as an accurate molecular proxy of tumor biology and reliably predict the response to tyrosine kinase therapy. In addition, several trials have demonstrated the high accuracy of microRNA (miRNA) platforms in discerning cancerous versus benign nodules in high-risk, screened patients. Despite the promise of these platforms, issues remain, including varying sensitivities and specificities between competing platforms and a lack of standardization of techniques and downstream processing. In the present report, the clinical applications of liquid biopsy technologies, including circulating tumor cells, proteomics, miRNA, and cfDNA for NSCLC, are reviewed and insight is provided into the diagnostic and therapeutic implications and challenges of these platforms.

show abstract

Section: Cfdnamentioning

confidence: 99%

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Levy

Cordova

et al. 2016

The Oncologist

View full text Add to dashboard Cite

show abstract

“…27 Levels of ctDNA in blood can vary widely between patients due to differences in tumor DNA release mechanisms and the effectiveness of cfDNA clearance, with estimates of the proportion of ctDNA from total cfDNA varying from 0.01% to 90%. 20,28 Serum cfDNA levels are significantly higher than plasma levels 20,[29][30][31][32][33] due to clotting of white blood cells in the collection tube, leading to their lysis. 20,32,33 Consequently, serum ctDNA is diluted by genomic DNA released from white blood cells, and plasma is preferred as a source of ctDNA.…”

Section: Liquid Biopsy Using Ctdna In Bloodmentioning

confidence: 99%

Future perspectives of circulating tumor DNA in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Tumor biopsy is currently the gold standard for diagnosis and in determining cell signaling pathways involved in the development of treatment resistance. However, there are major challenges with this technique, including the need for serial sampling to monitor treatment resistance, which is invasive and also has the potential for selection bias due to intra-tumoral and inter-tumoral heterogeneity. These challenges highlight the need for more effective methods for obtaining Tumor samples. Liquid biopsy analyzes genetic material or tumor cells shed into the blood from the primary tumor and metastatic sites and consequently provides a comprehensive, real-time picture of the tumor burden in an individual patient. Indeed, liquid biopsy has the potential to revolutionize cancer management. Here, we review recent studies on the potential clinical applications of liquid biopsy using circulating tumor DNA in colorectal cancer, including screening, diagnosis, detection of minimal residual disease after surgery, detection of recurrence, prognosis, predicting treatment response, monitoring tumor burden or response during treatment, and tracking resistance. We also discuss recent data demonstrating the utility of detecting KRAS-mutated circulating tumor DNA, both at diagnosis to determine an appropriate treatment strategy and during anti-epidermal growth factor receptor therapy to predict treatment resistance. The future integration of liquid biopsy into clinical practice is discussed, together with alternative approaches and key questions that need to be answered in future clinical studies before this technology can be implemented and used routinely.

show abstract

“…Chang et al [6] used QIAamp blood and PicoGreen cf-DNA kits for the extraction and quantification of serum cf-DNA, respectively, and found that elevated cf-DNA in MI patients could complement troponin (Tn) and creatine kinase-MB (CK-MB) in a multiple marker test format. Furthermore, using a ﬂuorescent assay, Shimony et al [7] found that cf-DNA concentrations were higher in ST-elevation myocardial infarction (STEMI) and were correlated with the levels of established markers of myocardial necrosis such as cardiac Tn I (cTnI) and CK. In addition to these studies, others have demonstrated the prognostic signiﬁcance of cf-DNA in MI patients.…”

Section: Introductionmentioning

confidence: 99%

Cell-Free Circulating DNA: A New Biomarker for the Acute Coronary Syndrome

Cui¹,

Fan²,

Jing³

et al. 2013

Cardiology

View full text Add to dashboard Cite

Background: In recent studies, concentrations of cell-free circulating DNA (cf-DNA) have been correlated with clinical characteristics and prognosis in several diseases. The relationship between cf-DNA concentrations and the acute coronary syndrome (ACS) remains unknown. Moreover, no data are available for the detection cf-DNA in ACS by a branched DNA (bDNA)-based Alu assay. The aim of the present study was to investigate cf-DNA concentrations in ACS and their relationship with clinical features. Methods: Plasma cf-DNA concentrations of 137 ACS patients at diagnosis, of 60 healthy individuals and of 13 patients with stable angina (SA) were determined using a bDNA-based Alu assay. Results: ACS patients (median 2,285.0, interquartile range 916.4–4,857.3 ng/ml), especially in ST-segment elevation myocardial infarction patients (median 5,745.4, interquartile range 4,013.5–8,643.9 ng/ml), showed a signiﬁcant increase in plasma cf-DNA concentrations compared with controls (healthy controls: median 118.3, interquartile range 81.1–221.1 ng/ml; SA patients: median 202.3, interquartile range 112.7–256.1 ng/ml) using a bDNA-based Alu assay. Moreover, we found positive correlations between cf-DNA and Gensini scoring and GRACE (Global Registry of Acute Coronary Events) scoring in ACS. Conclusion: cf-DNA may be a valuable marker for diagnosing and predicting the severity of coronary artery lesions and risk stratification in ACS.

show abstract

Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients

Abstract: With this method, CFD levels correlated with the levels of established markers of myocardial necrosis but not with EF. The kinetic pattern of CFD release after STEMI and its prognostic value require further investigation.

Cited by 66 publications

References 14 publications

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Future perspectives of circulating tumor DNA in colorectal cancer

Cell-Free Circulating DNA: A New Biomarker for the Acute Coronary Syndrome

Contact Info

Product

Resources

About